The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. (Q53998964)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. (English)

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

4

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

23 May 2018

PMC publication ID

3

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

author name string

Mark S Freedman

1

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Jerry S Wolinsky

2

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Tomas P Olsson

5

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Aaron E Miller

6

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Karthinathan Thangavelu

7

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Myriam Benamor

8

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Philippe Truffinet

9

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Paul W O'Connor

10

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

TEMSO and TOWER Study Groups

11

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

publication date

17 March 2017

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

24

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

4

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

535-539

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

23 May 2018

Risk evaluation and monitoring in multiple sclerosis therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

23 May 2018

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

23 May 2018

Review: Natalizumab in the treatment of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

23 May 2018

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

23 May 2018

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

13 August 2018

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5891690

13 August 2018

Identifiers

10.1177/1352458517695468

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 May 2018

http://europepmc.org/abstract/PMC/5891690

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53998964&oldid=1002942689"